Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets’ Disease-Associated Uveitis: A Systematic Review and Meta-Analysis
We conducted a systematic review and meta-analysis to determine the effectiveness and safety of anti-tumor necrosis factor-alpha (TNF-α) agents in the treatment of Behcets’ disease (BD)-associated uveitis.
MethodThree electronic databases, Embase, MEDLINE, and the Cochrane Library, were searched for eligible papers focusing on the anti-TNF-α agents treatment in BD-associated uveitis with at least 6 months follow-up time. A systematic review and meta-analysis was conducted on selected papers with appropriate clinical and methodological homogeneity. The effectiveness outcomes included inflammation remission, visual acuity (VA) improvement, central macular thickness (CMT) decrease, corticosteroid (CS)-sparing effects, and the safety outcomes included minor and severe drug-related adverse events (AEs).
ResultFrom Jan 2010 to Dec 2019, there were 504 records produced in total, in which 18 clinical trials were selected for meta-analysis (15 trials were retrospective studies, and 3 were prospective studies). The number of patients in each study ranged from 11 to 163 and the mean follow-up time from 0.9 to 6.44 years. During the follow-up, the pooled inflammation remission rate was 68% with a 95% confidence interval (CI) of 0.59–0.79, VA improvement rate was 60% (95% CI 0.47–0.77), CMT decrease was 112.70 μm (95% CI 72.8–153.0 μm). The proportions of patients who had CS-suspended and CS-tapered reached 38% (95% CI 0.23–0.65) and 34% (95% CI 0.16–0.70), respectively. The severe AEs were reported but not common, which included severe infusion reactions, pneumonia, bacteremia, tuberculosis, melanoma, and lymphoma.
ConclusionAnti-TNF-α agents treatment has high effectiveness including efficient inflammation remission, satisfactory VA improvement, obvious CMT reduction, and significant CS-sparing effects. Although some drug-related AEs were reported, the incidence of severe AEs was acceptable. Anti-TNF-α agents treatment is a promising option for controlling BD-associated uveitis.
CITE THIS COLLECTION
REFERENCES
- https://doi.org//10.3109/09273948.2013.779727
- https://doi.org//10.3109/09273948.2010.483314
- https://doi.org//10.1136/annrheumdis-2012-eular.2670
- https://doi.org//10.1136/bjo.2006.103721
- https://doi.org//10.1136/annrheumdis-2013-eular.1874
- https://doi.org//10.1093/rheumatology/keu266
- https://doi.org//10.2147/BTT.S27343
- https://doi.org//10.3349/ymj.2012.53.1.35
- https://doi.org//10.3109/02713689209001814
- https://doi.org//10.1038/eye.2009.203
- https://doi.org//10.1136/annrheumdis-2017-eular.6226
- https://doi.org//10.1016/j.ejr.2017.08.001
- https://doi.org//10.1007/s10067-016-3480-x
- https://doi.org//10.1007/bf00915816
SHARE
Usage metrics
![Frontiers in Pharmacology](https://s3-eu-west-1.amazonaws.com/876az-branding-figshare/frontiers/logo.png)